These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22723122)

  • 1. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.
    Dai W; Jin W; Zhang J; Wang X; Wang J; Zhang X; Wan Y; Zhang Q
    Pharm Res; 2012 Oct; 29(10):2902-11. PubMed ID: 22723122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
    Li H; Yuan D; Sun M; Ping Q
    Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
    Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
    Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
    Li X; Wu M; Pan L; Shi J
    Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
    Liu Y; Kim YJ; Siriwon N; Rohrs JA; Yu Z; Wanga P
    Biotechnol Bioeng; 2018 Jun; 115(6):1403-1415. PubMed ID: 29457630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
    He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
    Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
    Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
    Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
    Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis.
    Wang F; Li Y; Jiang H; Li C; Li Z; Qi C; Li Z; Gao Z; Zhang B; Wu J
    Int J Nanomedicine; 2021; 16():4001-4016. PubMed ID: 34135585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of octreotide-modified oleanolic acid liposomes to somatostatin receptor overexpressing tumor cells.
    Wang Q; Zhu R; Wang M; Xing S; Li L; He Y; Cao W; Gao D
    Nanomedicine (Lond); 2017 Apr; 12(8):927-940. PubMed ID: 28338414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
    Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
    Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
    Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
    Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
    Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.
    Shim G; Lee S; Choi J; Lee S; Kim CW; Oh YK
    Pharm Res; 2014 Aug; 31(8):2178-85. PubMed ID: 24562810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
    Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
    Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy.
    Zhang X; Yang C; Zhou J; Huo M
    Small; 2016 Jul; 12(26):3578-90. PubMed ID: 27244649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.